

Version 1.0.3

Submission

[Home](#) > [Submission](#)

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/04/2019
Deadline Date	30/04/2019
Date Submitted	26/04/2019
Type	Performance In Delivering
NHS provider	Maidstone and Tunbridge Wells NHS Trust

Showing records 1 to 8 of 8.

Pages: 1

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
37909	13/LO/1557	135995	CALM-NET: A Phase 4, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving D	Number Agreed	2	2	Not Available / Not Agreed			07/07/2018	0	Recruitment Finished	Rare pt population, difficult to screen/recru eligible pts
37910	17/LO/0441	222471	KEYNOTE-604 MK-3475: A phase III randomised double-blind placebo-controlled trial of pembrolizumab (MK-3475) in combination with etoposide/platinum (Cisplatin or Carboplatin) for the first-line treatment of subjects with extensive stage small cell lu	Number Agreed	4	4	Date Agreed	05/03/2018	1	10/07/2018	3	Recruitment Finished	study reached overall recruitment target
37911	16/LO/1106	207909	A randomised double blind phase III study of Pembrolizumab () plus Chemotherapy vs Placebo plus Chemotherapy for previously untreated inoperable locally recurrent or metastatic triple negative breast cancer (keynote 355)	Number Agreed	4	4	Not Available / Not Agreed			03/07/2018	0	Recruitment Finished	Although C&C issued, not activated for recruitment due to capacity issues within delivery team - sponso aware.
37912	17/LO/0347	221524	KEYNOTE 522 - A Phase III randomized double lind study to evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	Number Agreed	4	4	Not Available / Not Agreed			03/07/2018	0	Recruitment Finished	Overall study recruitment reached before site could recrui pt
37913	17/LO/0825	223457	GS-US-445-4189 A randomised phase 2 double-blind placebo-controlled study to assess the safety and efficacy of filgotinib GS-9876 and GS-4059 in adult subjects with active sjogren's syndrome GISST	Number Agreed	2	2	Date Agreed	01/04/2018	0	05/09/2018	0	Recruitment Finished	pts not ill enough to meet inc/exc criteria making it difficult to consent pts
37914	16/LO/0880	205661	CREDO 2 - A randomised, double blind, parallel-group, placebo and active controlled, multicentre phase III study of the efficacy and safety of Olokizumab in subjects with moderately to severe active Rheumatoid Arthritis inadequately controlled by Metho	Number Agreed	6	6	Not Available / Not Agreed			13/11/2018	1	Recruitment Finished	Pts screened but not eligible due to not fitting the inclusion criteria.
37915	17/SW/0221	232448	Surpass	Number Agreed	2	2	Date Agreed	27/06/2019	0	11/10/2018	0	Withdrawn By Sponsor	Site closed by sponsor due to no pts recruited. This was due to a change in standard practice making eligibility of patients difficult
37916	16/LO/1069	200813	PALLAS	Number Agreed	10	10	Date Agreed	30/09/2018	8	31/10/2018	12	Recruitment Finished	

Showing records 1 to 8 of 8.
Pages: 1

< Back

Copyright (c) Exbos Limited 2013. All Rights Reserved. Web site developed in the City of Leeds, England by [Exbos Limited](#) the bespoke software specialists.

